Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 431,784
  • Shares Outstanding, K 126,623
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,830 K
  • 60-Month Beta 2.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.30
Trade ATOS with:

Options Overview

Details
  • Implied Volatility 100.81%
  • Historical Volatility 78.77%
  • IV Percentile 4%
  • IV Rank 1.04%
  • IV High 582.41% on 12/21/20
  • IV Low 95.76% on 08/23/21
  • Put/Call Vol Ratio 0.12
  • Today's Volume 4,730
  • Volume Avg (30-Day) 13,686
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 234,270
  • Open Int (30-Day) 252,791

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.04 +12.17%
on 08/17/21
4.31 -20.88%
on 09/02/21
+0.28 (+8.95%)
since 08/16/21
3-Month
2.75 +24.00%
on 08/03/21
9.80 -65.20%
on 06/25/21
-1.24 (-26.67%)
since 06/16/21
52-Week
0.81 +320.99%
on 12/17/20
9.80 -65.20%
on 06/25/21
+1.16 (+51.56%)
since 09/16/20

Most Recent Stories

More News
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Atossa Therapeutics, Inc. - ATOS

New York, New York--(Newsfile Corp. - September 13, 2021) -  Levi & Korsinsky announces that it has commenced an investigation of Atossa Therapeutics, Inc. (NASDAQ: ATOS) concerning possible breaches...

ATOS : 3.41 (+2.40%)
Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote

Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor

ATOS : 3.41 (+2.40%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Atossa Therapeutics, Inc. - ATOS

New York, New York--(Newsfile Corp. - August 25, 2021) -  Levi & Korsinsky announces it has commenced an investigation of Atossa Therapeutics, Inc. (NASDAQ: ATOS) concerning possible breaches of fiduciary...

ATOS : 3.41 (+2.40%)
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast...

ATOS : 3.41 (+2.40%)
Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious...

ATOS : 3.41 (+2.40%)
Physician-Scientist Steven Quay: Forensic examination of Wuhan Institute of Virology COVID-19 patient specimens from December 2019 reveals extensive laboratory contamination, including evidence of genetic manipulation of the Nipah Virus, a BSL-4 pathogen more lethal than Ebola

/PRNewswire/ -- Physician-Scientist and a group of international scientists have published a pre-print, available , entitled, "CONTAMINATION OR VACCINE RESEARCH? RNA Sequencing data of early COVID-19...

ATOS : 3.41 (+2.40%)
Physician-Scientist Steven Quay and an International Team of Scientists and Investigators Provide Science-Based Analysis of the Origin of COVID-19 to the US Congress

/PRNewswire/ -- An international team of scientists and data analysts, led by Physician-Scientist , MD, PhD, has published a paper entitled, "Science Not Speculation Should Inform the Investigation of...

ATOS : 3.41 (+2.40%)
Thinking about buying stock in Ashford Hospitality Trust, Clovis Oncology, Exela Technologies, Wipro, or Atossa Therapeutics?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AHT, CLVS, XELA, WIT, and ATOS.

ATOS : 3.41 (+2.40%)
XELA : 2.10 (+1.94%)
CLVS : 4.61 (+3.60%)
AHT : 13.99 (-6.04%)
WIT : 9.47 (-1.76%)
Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia

Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and "Long Haul" patients with post-infection pulmonary disease

ATOS : 3.41 (+2.40%)
Thinking about buying stock in Provention Bio, Virgin Galactic, Staffing 360 Solutions, Atossa Therapeutics, or Marin Software?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRVB, SPCE, STAF, ATOS, and MRIN.

ATOS : 3.41 (+2.40%)
STAF : 2.11 (-1.86%)
MRIN : 5.54 (-0.89%)
PRVB : 6.45 (+0.62%)
SPCE : 24.49 (+2.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

3rd Resistance Point 3.64
2nd Resistance Point 3.54
1st Resistance Point 3.48
Last Price 3.41
1st Support Level 3.32
2nd Support Level 3.22
3rd Support Level 3.16

See More

52-Week High 9.80
Fibonacci 61.8% 6.37
Fibonacci 50% 5.31
Fibonacci 38.2% 4.24
Last Price 3.41
52-Week Low 0.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar